DLBCL

Conference Insider

Avelumab Plus R-CHOP Effective for Newly Diagnosed DLBCL

12/10/2020

Avelumab plus R-CHOP yielded high rates of complete response with manageable toxicity in a cohort of patients with newly diagnosed DLBCL.

Avelumab plus R-CHOP yielded...

12/10/2020

Oncology

Conference Insider

Mosunetuzumab Safe, Effective for Elderly Patients With DLBCL

12/07/2020

Single-agent mosunetuzumab shows efficacy, remarkable safety, as a chemo-free option for previously untreated elderly/unfit patients with DLBCL.

Single-agent mosunetuzumab shows...

12/07/2020

Oncology

Conference Insider

Polatuzumab Vedotin Plus Venetoclax, Rituximab Shows Promise in R/R DLBCL

12/03/2020

Polatuzumab vedotin plus venetoclax with rituximab shows promise in the treatment of patients with R/R DLBCL, according to phase 1b/2 study findings.

Polatuzumab vedotin plus...

12/03/2020

Oncology

Conference Insider

Frailty Tied to Increased 1-Year Mortality in Patients with Newly Diagnosed DLBCL

12/02/2020

According to data being presented at the virtual ASH Annual Meeting and Exposition, fragility in patients with DLBCL is significantly associated with 1-year mortality.

According to data being...

12/02/2020

Oncology

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

September 18 ⁠–⁠ September 20

September 20 ⁠–⁠ September 22

September 21 ⁠–⁠ September 22

September 30 ⁠–⁠ October 2

October 1 ⁠–⁠ October 2

October 2 ⁠–⁠ October 5

October 5 ⁠–⁠ October 6

October 14 ⁠–⁠ October 16

October 16 ⁠–⁠ October 19

October 19 ⁠–⁠ October 20

See Full Calendar

DLBCL

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products